Moderna Inc on Tuesday sought conditional marketing authorization with the European Medicines Agency for use of its COVID-19 vaccine in children in the age-group of 6-11 years.
The vaccine was authorized for use in teens aged 12 to 17 years by the European Union in July, but several countries including Sweden have paused its use for people aged 30 and younger due to rare heart-related side-effects.
The drugmaker sought US authorization of its vaccine for use in teens in June and is awaiting a decision by the US Food and Drug Administration.
“This marks our first submission for the use of our vaccine in this age group,” said Stéphane Bancel, Chief Executive of Moderna, adding the company will submit the data to other regulatory agencies around the world.
WHO warns of shortage of 1-2 bln COVID-19 vaccine syringesThere could be a shortage of one to two billion syringes needed to administer COVID-19 vaccinations in 2022 which could also impact routine ... Coronavirus
Global COVID-19 infections pass 250 million: AFP tallyMore than 250 million COVID-19 infections have been recorded worldwide since the start of the pandemic, according to an AFP count compiled from ... Coronavirus
Explainer: How US COVID-19 rules on international travel are changingMore than a year and a half after COVID-19 concerns prompted the US to close its borders to international travelers from countries including Brazil, ... Coronavirus
Moderna COVID-19 shot could start being used in children, teens ‘within weeks’: CEOModerna Inc's COVID-19 vaccine could start to be used in children and teens in the United States within weeks, its chief executive said in an ... Coronavirus